Re #Molnupiravir is currently being evaluated for inclusion into the WHO living guideline on #COVID19 therapeutics and is pending authorization for …


Re #Molnupiravir is currently being evaluated for inclusion into the WHO living guideline on #COVID19 therapeutics and is pending authorization for its use from regulatory bodies. If approved, it will be the 1st oral medicine for non-hospitalized mild-to-moderate COVID-19 patients.

LikedLiked 19 views